it has been found that the abovementioned aim is achieved by means of the compound 4 -[ 4 -( 2 - pyrrolylcarbonyl )- 1 - piperazinyl ]- 3 - trifluoromethylbenzoylguanidine hydrochloride 1 the compound of formula 1 is not hygroscopic and dissolves readily in physiologically acceptable solvents . it is also characterized by a high degree of stability . unlike the compound of formula 1 , does not meet the requirements set out hereinbefore , however . accordingly , in one aspect , the present invention relates to the compound of formula 1 as such . in another aspect , the present invention relates to the compound of formula 1 in the form of its hydrates , preferably in the form of its monohydrate or hemihydrate . in another aspect , the present invention relates to the use of the compound of formula 1 as a medicament . the present invention further relates to the use of the compound of formula 1 , optionally in the form of its hydrates , for preparing a pharmaceutical composition for treating diseases in which inhibitors of the cellular na + / h + exchange may develop a therapeutic benefit . the present invention further relates to the use of the compound of formula 1 to prepare a pharmaceutical composition for treating cardiovascular diseases . the present invention further relates to the use of the compound of formula 1 to prepare a pharmaceutical composition for treating arrhythmia such as occurs in hypoxia , for example . the present invention further relates to the use of the compound of formula 1 to prepare a pharmaceutical composition for treating complaints connected with ischaemia ( such as : cardiac , cerebral , gastrointestinal ( such as mesenteric thrombosis / embolism ), pulmonary , renal ischaemia , ischaemia of the liver , and ischaemia of the skeletal muscles . the present invention further relates to the use of the compound of formula 1 to prepare a pharmaceutical composition for treating diseases selected from the group consisting of coronary heart disease , cardiac infarct , angina pectoris , stable angina pectoris , ventricular arrhythmia , subventricular arrhythmias , cardiac insufficiency , and also for assisting bypass operations , for assisting open heart surgery , for assisting operations which require an interruption to the blood supply to the heart and to assist in heart transplants , embolism in the pulmonary circulation , acute or chronic kidney failure , chronic renal insufficiency , cerebral infarct , reperfusion damage in the restoration of blood supply to areas of the brain after the dissolving of vascular occlusions and acute , and chronic circulatory disorders of the brain . the present invention further relates to the use of the compound of formula 1 to prepare a pharmaceutical composition for treating diseases in which the use of cardioprotective active substances may be of therapeutic benefit . the present invention further relates to the use of the compound of formula 1 to prepare a pharmaceutical composition for treating cancers , benign tumors or , for example , prostatic hypertrophy , atherosclerosis , organ hypertrophy and hyperplasia , fibrotic diseases , and late complications of diabetes . the compound of formula 1 may be used as an aqueous injectable solution ( e . g ., for intravenous , intramuscular , or subcutaneous administration ), as a tablet , as a suppository , as an ointment , as a plaster for transdermal administration , as an aerosol for inhalation into the lungs or as a nasal spray . the content of active substance in a tablet or a suppository is between 5 mg and 200 mg , preferably between 10 mg and 50 mg . for inhalation , the single dose is between 0 . 05 mg and 20 mg , preferably between 0 . 2 mg and 5 mg . for parenteral injection , the single dose is between 0 . 1 mg and 50 mg , preferably between 0 . 5 mg and 20 mg . the doses specified above may be given several times a day if necessary . the following are some examples of pharmaceutical preparations containing the active substance : wo 00 / 17176 discloses possible methods of production which can be used to synthesize the free base 4 -[ 4 -( 2 - pyrrolylcarbonyl )- 1 - piperazinyl ]- 3 - trifluoromethylbenzoylguanidine . starting from this compound , the following possible methods of synthesizing the compound of formula 1 are illustrated by way of example . 15 . 1 g of 4 -[ 4 -( 2 - pyrrolylcarbonyl )- 1 - piperazinyl ]- 3 - trifluoromethylbenzoylguanidine is taken up in 151 ml of methanol and the resulting suspension is cooled to about 10 ° c . 16 ml of a saturated ethereal hcl solution are added to this suspension which is thus acidified to a ph of between 1 and 2 . stirring is continued , while cooling with ice , until crystallization is complete . the crystals are suction filtered , washed with cold methanol , and then with cold diethyl ether . yield : 16 . 19 g ; melting point : 223 ° c . ( uncorrected ). 15 . 0 kg of 4 -[ 4 -( 2 - pyrrolylcarbonyl )- 1 - piperazinyl ]- 3 - trifluoromethylbenzoylguanidine is taken and combined with 120 l of ethyl acetate . the suspension is heated to about 45 ° c . and combined with 30 l of water . the resulting mixture is stirred for about 15 minutes and the aqueous phase is then separated off . a solution of 3 . 62 kg of concentrated hydrochloric acid in 20 l of water is added to the organic phase at a constant temperature . within about 1 to 2 hours , the mixture is cooled to 25 ° c . to 20 ° c . the hydrochloride obtained is separated off , washed with 50 l of ethyl acetate , and dried in vacuo at about 60 ° c . yield : 78 %; melting point : 225 ° c . ± 5 ° c . ( dsc at a heating rate of 10k / min ). 109 . 4 g of 4 -[ 4 -( 2 - pyrrolylcarbonyl )- 1 - piperazinyl ]- 3 - trifluoromethylbenzoylguanidine is suspended in 1 . 5 l of water and heated to about 50 ° c . 26 . 1 ml of concentrated aqueous hydrochloric acid is diluted with 300 ml of water and added dropwise to the preheated suspension within about 20 minutes . the mixture is stirred for about 15 minutes at constant temperature . then the temperature is lowered to about 35 ° c . with stirring over a period of about 1 . 5 hours . it is then cooled to 5 ° c . to 10 ° c . and stirred for another hour at this temperature . the crystals obtained are separated off , washed with a little water , and dried in vacuo at about 50 ° c . yield : 116 . 5 g ; melting point : 180 ° c . ± 5 ° c . ( dsc at a heating rate of 10 k / min ).